Proteomics International Laboratories Ltd

ASX:PIQ Stock Report

Market Cap: AU$134.2m

Proteomics International Laboratories Management

Management criteria checks 2/4

Proteomics International Laboratories' CEO is Richard Lipscombe, appointed in Jan 2001, has a tenure of 23.5 years. total yearly compensation is A$442.00K, comprised of 79.2% salary and 20.8% bonuses, including company stock and options. directly owns 12.54% of the company’s shares, worth A$16.83M. The average tenure of the management team and the board of directors is 2.8 years and 2.5 years respectively.

Key information

Richard Lipscombe

Chief executive officer

AU$442.0k

Total compensation

CEO salary percentage79.2%
CEO tenure23.5yrs
CEO ownership12.5%
Management average tenure2.8yrs
Board average tenure2.5yrs

Recent management updates

Most Shareholders Will Probably Find That The CEO Compensation For Proteomics International Laboratories Limited (ASX:PIQ) Is Reasonable

Nov 16
Most Shareholders Will Probably Find That The CEO Compensation For Proteomics International Laboratories Limited (ASX:PIQ) Is Reasonable

Here's Why We Think Proteomics International Laboratories Limited's (ASX:PIQ) CEO Compensation Looks Fair for the time being

Nov 17
Here's Why We Think Proteomics International Laboratories Limited's (ASX:PIQ) CEO Compensation Looks Fair for the time being

Recent updates

Most Shareholders Will Probably Find That The CEO Compensation For Proteomics International Laboratories Limited (ASX:PIQ) Is Reasonable

Nov 16
Most Shareholders Will Probably Find That The CEO Compensation For Proteomics International Laboratories Limited (ASX:PIQ) Is Reasonable

Calculating The Fair Value Of Proteomics International Laboratories Limited (ASX:PIQ)

Sep 29
Calculating The Fair Value Of Proteomics International Laboratories Limited (ASX:PIQ)

We're Hopeful That Proteomics International Laboratories (ASX:PIQ) Will Use Its Cash Wisely

May 10
We're Hopeful That Proteomics International Laboratories (ASX:PIQ) Will Use Its Cash Wisely

Here's Why We Think Proteomics International Laboratories Limited's (ASX:PIQ) CEO Compensation Looks Fair for the time being

Nov 17
Here's Why We Think Proteomics International Laboratories Limited's (ASX:PIQ) CEO Compensation Looks Fair for the time being

Is Proteomics International Laboratories (ASX:PIQ) In A Good Position To Invest In Growth?

Aug 09
Is Proteomics International Laboratories (ASX:PIQ) In A Good Position To Invest In Growth?

We Think Proteomics International Laboratories (ASX:PIQ) Can Afford To Drive Business Growth

Oct 20
We Think Proteomics International Laboratories (ASX:PIQ) Can Afford To Drive Business Growth

We're Not Worried About Proteomics International Laboratories' (ASX:PIQ) Cash Burn

May 31
We're Not Worried About Proteomics International Laboratories' (ASX:PIQ) Cash Burn

CEO Compensation Analysis

How has Richard Lipscombe's remuneration changed compared to Proteomics International Laboratories's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-AU$6m

Sep 30 2023n/an/a

-AU$6m

Jun 30 2023AU$442kAU$350k

-AU$6m

Mar 31 2023n/an/a

-AU$6m

Dec 31 2022n/an/a

-AU$6m

Sep 30 2022n/an/a

-AU$5m

Jun 30 2022AU$330kAU$265k

-AU$5m

Mar 31 2022n/an/a

-AU$5m

Dec 31 2021n/an/a

-AU$4m

Sep 30 2021n/an/a

-AU$4m

Jun 30 2021AU$298kAU$250k

-AU$3m

Mar 31 2021n/an/a

-AU$3m

Dec 31 2020n/an/a

-AU$2m

Sep 30 2020n/an/a

-AU$2m

Jun 30 2020AU$299kAU$250k

-AU$2m

Mar 31 2020n/an/a

-AU$2m

Dec 31 2019n/an/a

-AU$2m

Sep 30 2019n/an/a

-AU$2m

Jun 30 2019AU$207kAU$185k

-AU$2m

Mar 31 2019n/an/a

-AU$2m

Dec 31 2018n/an/a

-AU$2m

Sep 30 2018n/an/a

-AU$2m

Jun 30 2018AU$156kAU$170k

-AU$1m

Compensation vs Market: Richard's total compensation ($USD299.38K) is about average for companies of similar size in the Australian market ($USD301.23K).

Compensation vs Earnings: Richard's compensation has increased whilst the company is unprofitable.


CEO

Richard Lipscombe

23.5yrs

Tenure

AU$442,000

Compensation

Dr. Richard John Lipscombe, Ph D (London), MA (Oxford), co-founded Proteomics International Laboratories Limited in 2001 and serves as its Managing Director and Director since June 09, 2014. Mr. Lipscombe...


Leadership Team

NamePositionTenureCompensationOwnership
Richard Lipscombe
Co-Founder23.5yrsAU$442.00k12.54%
A$ 16.8m
Jacqueline Gray
Chief Financial Officer3yrsAU$305.30k0%
A$ 0
John Morrison
Head of Business Developmentno datano datano data
Scott Bringans
Head of Research2.5yrsno datano data
Pearl Tan
Head of Product Development2yrsno datano data
Kirsten Peters
Head of Clinical Studiesno datano datano data
Karen Logan
Company Secretaryno datano datano data

2.8yrs

Average Tenure

Experienced Management: PIQ's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Richard Lipscombe
Co-Founder10.1yrsAU$442.00k12.54%
A$ 16.8m
Neville Gardiner
Independent Non-Executive Chairman2.7yrsAU$129.66k0.090%
A$ 120.6k
Eleuterio Ferrannini
Member of Clinical Advisory Board2.3yrsno datano data
Ian Moore
Independent Non-Executive Director7.8yrsAU$45.00k0.75%
A$ 1.0m
Robyn Elliott
Independent Non-Executive Director2.7yrsAU$73.12kno data
Paul House
Independent Non-Executive Director6.7yrsAU$49.73k0.79%
A$ 1.1m
Tim Davis
Member of Clinical Advisory Board2.3yrsno datano data
Alexander Turchin
Member of Clinical Advisory Board2.3yrsno datano data
Davida Kruger
Member of Clinical Advisory Boardno datano datano data
Michael Shanik
Member of Clinical Advisory Board2.3yrsno datano data
Merlin Thomas
Member of Clinical Advisory Board2.3yrsno datano data
Neil Sholnik
Member of Clinical Advisory Boardno datano datano data

2.5yrs

Average Tenure

Experienced Board: PIQ's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.